• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Thought Leader Insight & Analysis Report - Osteoporosis Q4 2011 Product Image

Thought Leader Insight & Analysis Report - Osteoporosis Q4 2011

  • ID: 2050491
  • October 2011
  • 134 Pages
  • Medpredict

Osteoporosis Thought Leader Panel #53 summarizes an Advisory Board that BOLT International / MedPredict conducted with our Thought Leaders after the ASBMR 2011. The Panel reviewed the highlights (lowlights) from the meeting, and touched on important pipeline advances for both antiresorptives (cathepsin K inhibitors, strontium, RANKL, oral calcitonin) and anabolics (anti-sclerostin, PTH variants). The Panel also weighed in on the FDA Advisory Committee Meeting on Bisphosphonates.

Executive Summary
- Report Highlights

Key Findings
- Evaluation Of Asbmr 2011
- Calcium Risk / Benefit In Osteoporosis Patients

Bisphosphonates
- Fda Acm
- Actonel; Risedronate (Warner Chilcott)

Rankl
- Prolia (Denosumab; Amgen)

Cathepsin K
- Odanacatib (Merck)
- Ono-5334 (Ono)

Pth
- Weekly Pth (Asahi Kasai)
- Pth 1-33 (Montefiore)
- Teriparatide Transdermal (Lilly / Transpharma)
- Ba-058 (Raduis / Nordic Bioscineces)

Sclerostin
- Romosozumab Amg-785 / Cdp7851 (Amgen / Ucb )
- Amg-167 (Amgen)
- Blosozumab; Ly2541546; Anti-Sclerostin Mab; Lilly
- Anti-Sclerostin Mab (Novartis)
- Anti-Sclerostin (Merck)
- Anti-Sclerostin (Japanese Company)

Serms
- Conbriza / Viviant (Bazedoxifene +/- Estrogen Tsec; Pfizer / Almirall)

Strontium
- Protelos (Strontium Ranelate; Servier)

Calcitonin
- Enteripep; Smc-021 (Nordic Bioscience / Novartis / Unigene / Emisphere)
- Ostora (Unigene / Tarsa)

Thought-Leader Discussions
- Interview Bje02609
- Interview Bje02612
- Interview Bje02613
- Interview Bje02618
- Interview Bje02622
- Interview Bje02623

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos